Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.935 USD | +0.76% | +11.15% | -19.79% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 63% by 2026.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-19.79% | 817M | - | ||
-3.83% | 184B | C+ | ||
-2.23% | 107B | C | ||
-4.47% | 67.52B | A | ||
+0.98% | 50.06B | B- | ||
+9.87% | 45.67B | B- | ||
+3.40% | 41B | B+ | ||
+3.54% | 26.73B | B | ||
+4.13% | 26.47B | A- | ||
+15.23% | 25.05B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- FNA Stock
- Ratings Paragon 28, Inc.